Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System? Alan Lyles Current Opinion 16 February 2017 Pages: 493 - 500
Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review Melina DritsakiFelix AchanaStavros Petrou Systematic Review 06 January 2017 Pages: 501 - 515
Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review James BrockbankSorrel Wolowacz Systematic Review 10 February 2017 Pages: 517 - 535
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Christopher CarrollPaul TappendenAnthony S. Wierzbicki Review Article 11 March 2017 Pages: 537 - 547
Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data Jason MadanKamran A. KhanSarah E. Lamb Original Research Article 06 January 2017 Pages: 549 - 559
Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study Matthew FranklinSarah DavisSteven Julious Original Research Article Open access 21 January 2017 Pages: 561 - 573
The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling Asrul Akmal ShafieHui Yee YeoAmar-Singh HSS Original Research Article 15 February 2017 Pages: 575 - 589
Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland Paul HanlyRebecca MaguireLinda Sharp Original Research Article 15 February 2017 Pages: 591 - 601
Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation” Afschin Gandjour Letter to the Editor 21 March 2017 Pages: 603 - 604
Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation” Monika WagnerMireille Goetghebeur Letter to the Editor 21 March 2017 Pages: 605 - 606